Dehydroevodiamine

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes[1]. Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells[2].

Product Specifications

CAS Number

[67909-49-3]

UNSPSC

12352005

Hazard Statement

H302, H317

Target

COX; NF-κB; NO Synthase; PGE synthase

Type

Natural Products

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dehydroevodiamine.html

Purity

99.93

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N2C(C([N-]C3=C4C=CC=C3)=C4CC2)=[N+](C)C5=C1C=CC=C5

Molecular Formula

C19H15N3O

Molecular Weight

301.34

Precautions

H302, H317

References & Citations

[1]Loh SH, et al. Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes. J Ethnopharmacol. 2014 May 14;153 (3) :753-62.|[2]Noh EJ, et al. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci. 2006 Jul 10;79 (7) :695-701. Epub 2006 Mar 6.